ABCD criteria to improve visual inspection with acetic acid (VIA) triage in HPV-positive women: a prospective study of diagnostic accuracy

Patrick Petignat, Bruno Kenfack, Ania Wisniak, Essia Saiji, Jean-Christophe Tille, Jovanny Tsuala Fouogue, Rosa Catarino, Eveline Tincho, Pierre Vassilakos, Patrick Petignat, Bruno Kenfack, Ania Wisniak, Essia Saiji, Jean-Christophe Tille, Jovanny Tsuala Fouogue, Rosa Catarino, Eveline Tincho, Pierre Vassilakos

Abstract

Objectives: A simple system for visual inspection with acetic acid assessment, named ABCD criteria, has been developed to increase accuracy for triaging of high-risk human papillomavirus (HPV)-positive women. This study aimed to determine the accuracy of ABCD criteria for the detection of histologically confirmed cervical intraepithelial neoplasia grade two or worse (CIN2+) in HPV-positive women living in a low-resource setting.

Design: Prospective study of diagnostic accuracy.

Setting: Cervical cancer screening programme based on a 3T-Approach (test, triage and treat) in the Health District of Dschang, West Cameroon.

Participants: Asymptomatic non-pregnant women aged 30-49 years were eligible to participate. Exclusion criteria included history of CIN treatment, anogenital cancer or hysterectomy. A total of 1980 women were recruited (median age, 40 years; IQR 35-45 years), of whom 361 (18.4%) were HPV-positive and 340 (94.2%) completed the trial.

Interventions: HPV-positive women underwent a pelvic examination for visual assessment of the cervix according to ABCD criteria. The criteria comprised A for acetowhiteness, B for bleeding, C for colouring and D for diameter. The ABCD criteria results were codified as positive or negative and compared with histological analysis findings (reference standards).

Primary outcome measure: Diagnostic performance of ABCD criteria for CIN2+, defined as sensitivity, specificity, negative and positive predictive values.

Results: ABCD criteria had a sensitivity of 77.5% (95% CI 61.3% to 88.2%), specificity of 42.0% (95% CI 36.5% to 47.7%), positive predictive value of 15.1% (95% CI 10.8% to 20.8%), and negative predictive value of 93.3% (95% CI 87.6% to 96.5%) for detection of CIN2 +lesions. Most (86.7%) of the ABCD-positive women were treated on the same day.

Conclusions: ABCD criteria can be used in the context of a single-visit approach and may be the preferred triage method for management of HPV-positive women in a low-income context.

Trial registration number: NCT03757299.

Keywords: community gynaecology; education & training (see medical education & training); gynaecological oncology; preventive medicine; public health.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
ABCD criteria for VIA interpretation in HPV-positive women. Criterion (A) Acetowhite area touching the transformation zone (absent on the native view and apparent after acetic acid application) is considered positive. Criterion (B) Bleeding without touching or after lightly touching (with a swab or speculum) the cervix is considered positive. Criterion (C) (optional)—colouring with VILI contributes to confirmation or identification of a faint acetowhite lesion. Criterion (D) Diameter of >5 mm (about the size of a pencil eraser) in an acetowhite area is considered positive. ABCD, acetowhiteness, bleeding, colouring and Diameter; diameter; HPV, human papillomavirus; VIA, visual inspection with acetic acid; VILI, visual inspection with Lugol’s iodine.
Figure 2
Figure 2
Flow chart of participants for the 3T-Approach in Cameroon. ABCD, acetowhiteness, bleeding, colouring and diameter; HPV, human papillomavirus.

References

    1. GLOBOCAN 2020. Global Cancer Observatory. International Agency for Research on Cancer [online]. Available: [Accessed 16 Nov 2021].
    1. Ronco G, Dillner J, Elfström KM, et al. . Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524–32. 10.1016/S0140-6736(13)62218-7
    1. World Health Organization . WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition [online]. Geneva, Switzerland. Available: [Accessed 1 Nov 2021].
    1. Sauvaget C, Fayette J-M, Muwonge R, et al. . Accuracy of visual inspection with acetic acid for cervical cancer screening. Int J Gynaecol Obstet 2011;113:14–24. 10.1016/j.ijgo.2010.10.012
    1. World Health Organization . Cervical cancer elimination initiative [online]. Available: [Accessed 9 Nov 2021].
    1. Tebeu P-M, Fokom-Domgue J, Crofts V, et al. . Effectiveness of a two-stage strategy with HPV testing followed by visual inspection with acetic acid for cervical cancer screening in a low-income setting. Int J Cancer 2015;136:E743–50. 10.1002/ijc.29250
    1. Untiet S, Vassilakos P, McCarey C, et al. . HPV self-sampling as primary screening test in sub-Saharan Africa: implication for a triaging strategy. Int J Cancer 2014;135:1911–7. 10.1002/ijc.28834
    1. Sankaranarayanan R, Nene BM, Shastri SS, et al. . HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385–94. 10.1056/NEJMoa0808516
    1. Denny L, Kuhn L, De Souza M, et al. . Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA 2005;294:2173–81. 10.1001/jama.294.17.2173
    1. Bigoni J, Gundar M, Tebeu P-M, et al. . Cervical cancer screening in sub-Saharan Africa: a randomized trial of VIA versus cytology for triage of HPV-positive women. Int J Cancer 2015;137:127–34. 10.1002/ijc.29353
    1. Lim JNW, Ojo AA. Barriers to utilisation of cervical cancer screening in Sub Sahara Africa: a systematic review. Eur J Cancer Care 2017;26:12444. 10.1111/ecc.12444
    1. Levy J, de Preux M, Kenfack B, et al. . Implementing the 3T-approach for cervical cancer screening in Cameroon: preliminary results on program performance. Cancer Med 2020;9:7293–300. 10.1002/cam4.3355
    1. Internation Agency for Research on Cancer . A practical manual on visual screening for cervical neoplasia. IARC Technical Publication Sankaranarayanan R, Wesley RS. 41st edn, 2003.
    1. Poli UR, Gowrishankar S, Swain M, et al. . Triage of women testing positive with the careHPV test on self-collected vaginal samples for cervical cancer screening in a low-resource setting. J Glob Oncol 2018;4:1–7. 10.1200/JGO.2016.008078
    1. Toliman PJ, Kaldor JM, Badman SG, et al. . Performance of clinical screening algorithms comprising point-of-care HPV-DNA testing using self-collected vaginal specimens, and visual inspection of the cervix with acetic acid, for the detection of underlying high-grade squamous intraepithelial lesions in Papua New Guinea. Papillomavirus Res 2018;6:70–6. 10.1016/j.pvr.2018.10.009
    1. Sherigar B, Dalal A, Durdi G, et al. . Cervical cancer screening by visual inspection with acetic acid--interobserver variability between nurse and physician. Asian Pac J Cancer Prev 2010;11:619–22.
    1. Manga S, Parham G, Benjamin N, et al. . Cervical cancer screening in Cameroon: interobserver agreement on the interpretation of digital cervicography results. J Low Genit Tract Dis 2015;19:288–94. 10.1097/LGT.0000000000000133
    1. Dareng EO, Olaniyan Y, Odutola MK, et al. . Secular trend in interobserver agreement of VIA diagnosis for cervical cancer screening in Nigeria. PLoS One 2018;13:e0208531. 10.1371/journal.pone.0208531
    1. Catarino R, Vassilakos P, Scaringella S, et al. . Smartphone use for cervical cancer screening in low-resource countries: a pilot study conducted in Madagascar. PLoS One 2015;10:e0134309. 10.1371/journal.pone.0134309
    1. Tran PL, Benski C, Viviano M, et al. . Performance of smartphone-based digital images for cervical cancer screening in a low-resource context. Int J Technol Assess Health Care 2018;34:337–42. 10.1017/S0266462318000260
    1. Grohar D, Vassilakos P, Benkortbi K, et al. . Scaling up community-based cervical cancer screening in Cameroon employing a single visit approach. Int J Gynecol Cancer 2020;30:1455–7. 10.1136/ijgc-2020-001422
    1. Reid R, Stanhope CR, Herschman BR, et al. . Genital warts and cervical cancer. IV. A colposcopic index for differentiating subclinical papillomaviral infection from cervical intraepithelial neoplasia. Am J Obstet Gynecol 1984;149:815–23. 10.1016/0002-9378(84)90597-0
    1. Strander B, Ellström-Andersson A, Franzén S, et al. . The performance of a new scoring system for colposcopy in detecting high-grade dysplasia in the uterine cervix. Acta Obstet Gynecol Scand 2005;84:1013–7. 10.1111/j.0001-6349.2005.00895.x
    1. Sankaranarayanan R, Wesley R, Thara S, et al. . Test characteristics of visual inspection with 4% acetic acid (VIA) and Lugol's iodine (VILI) in cervical cancer screening in Kerala, India. Int J Cancer 2003;106:404–8. 10.1002/ijc.11245
    1. Wesley R, Sankaranarayanan R, Mathew B, et al. . Evaluation of visual inspection as a screening test for cervical cancer. Br J Cancer 1997;75:436–40. 10.1038/bjc.1997.72
    1. Basu P, Sankaranarayanan R, Mandal R, et al. . Evaluation of downstaging in the detection of cervical neoplasia in Kolkata, India. Int J Cancer 2002;100:92–6. 10.1002/ijc.10445
    1. Kunckler M, Schumacher F, Kenfack B, et al. . Cervical cancer screening in a low-resource setting: a pilot study on an HPV-based screen-and-treat approach. Cancer Med 2017;6:1752–61. 10.1002/cam4.1089
    1. Goldhaber-Fiebert JD, Denny LE, De Souza M, et al. . The costs of reducing loss to follow-up in South African cervical cancer screening. Cost Eff Resour Alloc 2005;3:11. 10.1186/1478-7547-3-11
    1. Mutyaba T, Mirembe F, Sandin S, et al. . Male partner involvement in reducing loss to follow-up after cervical cancer screening in Uganda. Int J Gynaecol Obstet 2009;107:103–6. 10.1016/j.ijgo.2009.07.019
    1. Pinder LF, Parham GP, Basu P, et al. . Thermal ablation versus cryotherapy or loop excision to treat women positive for cervical precancer on visual inspection with acetic acid test: pilot phase of a randomised controlled trial. Lancet Oncol 2020;21:175–84. 10.1016/S1470-2045(19)30635-7

Source: PubMed

3
Subskrybuj